Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload
US12419964B2 · kind B2 · utility
0Cited by
1References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 2, 2024 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | Oct 2, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.